. 2021 Jul 3;2(8):100203. doi: 10.1016/j.jtocrr.2021.100203

Table 3.

Cox Proportional Hazard Model With Stabilized Inverse Probability Weighting Propensity and Propensity-Matched Analyses Stratified by Stage-Preferred Treatment Status

Care Delivery	Hazard Ratio (95% CI)	Unadjusted p Value	Adjusted p Value^a
Stratified by stage-preferred treatment
Stabilized inverse probability weighting^b
Among those with stage-preferred treatment
eMTOC vs. non-MTOC: metropolitan	0.95 (0.83, 1.09)	0.4811	0.7608
eMTOC vs. non-MTOC: regional	0.81 (0.7–0.93)	0.0040	0.0112
Non-MTOC: regional vs. metropolitan	1.18 (1.06–1.31)	0.0022	0.0064
Among those without stage-preferred treatment
eMTOC vs. non-MTOC: metropolitan	0.73 (0.61–0.86)	0.0003	0.0008
eMTOC vs. non-MTOC: regional	0.71 (0.59–0.84)	0.0001	0.0003
Non-MTOC: regional vs. metropolitan	1.03 (0.93–1.14)	0.5943	0.8553
Propensity matched^b
Among those with stage-preferred treatment
eMTOC vs. non-MTOC: metropolitan	0.8 (0.59–1.09)	0.1518	0.3237
eMTOC vs. non-MTOC: regional	0.76 (0.54–1.06)	0.1002	0.2272
Non-MTOC: regional vs. metropolitan	1.06 (0.83–1.34)	0.6486	0.8919
Among those without stage-preferred treatment
eMTOC vs. non-MTOC: metropolitan	0.48 (0.31–0.73)	0.0006	0.0018
eMTOC vs. non-MTOC: regional	0.53 (0.34–0.82)	0.0042	0.0117
Non-MTOC: regional vs. metropolitan	0.9 (0.73–1.13)	0.3705	0.6431
Stratified by stage-appropriate treatment
Stabilized inverse probability weighting^b
Among those with stage-appropriate treatment
eMTOC vs. non-MTOC: metropolitan	0.91 (0.8–1.03)	0.1244	0.2739
eMTOC vs. non-MTOC: regional	0.83 (0.73–0.95)	0.0061	0.0168
Non-MTOC: regional vs. metropolitan	1.09 (1–1.2)	0.0651	0.1552
Among those without stage-appropriate treatment
eMTOC vs. non-MTOC: metropolitan	0.69 (0.56–0.86)	0.0007	0.002
eMTOC vs. non-MTOC: regional	0.6 (0.48–0.74)	<0.0001	<0.0001
Non-MTOC: regional vs. metropolitan	1.15 (1.03–1.3)	0.0171	0.045
Propensity matched^b
Among those with stage-appropriate treatment
eMTOC vs. non-MTOC: metropolitan	0.71 (0.54–0.94)	0.0167	0.0440
eMTOC vs. non-MTOC: regional	0.75 (0.55–1.02)	0.0633	0.1514
Non-MTOC: regional vs. metropolitan	0.95 (0.77–1.17)	0.6187	0.8724
Among those without stage-appropriate treatment
eMTOC vs. non-MTOC: metropolitan	0.48 (0.28–0.8)	0.0049	0.0136
eMTOC vs. non-MTOC: regional	0.46 (0.27–0.78)	0.0041	0.0114
Non-MTOC: regional vs. metropolitan	1.03 (0.8–1.34)	0.7979	0.9645

Note: Excluding patients with unknown stage. Non-MTOC metropolitan: patients without care planning through the eMTOC, who received care within metropolitan Memphis; non-MTOC regional: patients without care planning through the eMTOC, who received care within institutions outside greater metropolitan Memphis.

CI, confidence interval; eMTOC, enhanced Multidisciplinary Thoracic Oncology Conference; MTOC, Multidisciplinary Thoracic Oncology Conference.

Multiple comparisons adjusted using Tukey’s correction.

Propensity adjusting for age, race, sex, insurance, and clinical stage.